Investors flocked to Moderna (NASDAQ: MRNA) last year with hopes its coronavirus vaccine program would bear fruit. Since, the company has become one of the first to commercialize a coronavirus vaccine. But Moderna's growth story isn't over. In this Motley Fool Live video recorded on Jan. 22, 2021, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss the elements that could push Moderna shares higher over the long term.
Source Fool.com